Market Place
Sourcing Support
Mesoblast To Host R&D Day On April 8, 2026
17 Mar 2026 //
GLOBENEWSWIRE
Ryoncil Profits Underpinning Substantial Growth Pipeline
26 Feb 2026 //
GLOBENEWSWIRE
Ryoncil Shows High Survival in EIND for SR-aGVHD
11 Feb 2026 //
GLOBENEWSWIRE
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L
19 Jan 2026 //
GLOBENEWSWIRE
ASH Study: Remestemcel-L Outperforms Ruxolitinib in Treating GVHD
11 Dec 2025 //
GLOBENEWSWIRE
Mesoblast Reports Strong Growth In Ryoncil Revenue At AGM Meeting
24 Nov 2025 //
GLOBENEWSWIRE
Mesoblast Partners with NIH for Pivotal aGvHD Cell Therapy Trial
24 Nov 2025 //
INDPHARMAPOST
Mesoblast, BMT CTN Launch Ryoncil® Trial for Severe Acute GVHD
20 Nov 2025 //
GLOBENEWSWIRE
Mesoblast To Discuss Rexlemestrocel-L & Opioid Cessation
04 Nov 2025 //
GLOBENEWSWIRE
Ryoncil® Net Revenues Increase 69% In Second Quarter Post Launch
19 Oct 2025 //
GLOBENEWSWIRE
Mesoblast Cell Therapy Deemed US Origin, Exempt From Tariffs
26 Sep 2025 //
GLOBENEWSWIRE
Successful Commercial Launch of Ryoncil
17 Jul 2025 //
GLOBENEWSWIRE
Mesoblast, FDA Align on Key Items for Revascor® Application
30 Jun 2025 //
GLOBENEWSWIRE
Mesoblast Advances FDA Approval for Revascor® and Ryoncil®
11 Jun 2025 //
GLOBENEWSWIRE
Mesoblast Cell Therapy Products Exempt from U.S. Tariffs
03 Apr 2025 //
GLOBENEWSWIRE
Mesoblast Requests FDA Meeting for Revascor® in Heart Failure
02 Apr 2025 //
GLOBENEWSWIRE
Ryoncil® is Now Available for Purchase in the United States
26 Mar 2025 //
GLOBENEWSWIRE
Mesoblast Added to S&P/ASX 200 INDEX
06 Mar 2025 //
GLOBENEWSWIRE
Pluri Congratulates Mesoblast on FDA Approval for GvHD Cell Therapy
19 Dec 2024 //
GLOBENEWSWIRE
FDA approves Mesoblast`s therapy for graft-versus-host disease
19 Dec 2024 //
REUTERS
Mesoblast’s RYONCIL® Is First FDA-Approved MSC Therapy
18 Dec 2024 //
GLOBENEWSWIRE
Mesoblast to be Added to Nasdaq Biotechnology Index
18 Dec 2024 //
GLOBENEWSWIRE
FDA Grant RMAT Designation for Revascor in Congenital Heart Disease
04 Dec 2024 //
GLOBENEWSWIRE
Revascor Improves Survival In Ischemic Heart Failure Patients
02 Dec 2024 //
GLOBENEWSWIRE
Depixus Unveils MAGNA One For Biomolecular Interactions
30 Sep 2024 //
BUSINESSWIRE
Mesoblast Reports Financial Results For Fiscal Year Ended June 30, 2024
28 Aug 2024 //
GLOBENEWSWIRE
FDA Accepts Mesoblast`s BLA For Ryoncil In Steroid-Refractory aGVHD
23 Jul 2024 //
GLOBENEWSWIRE
Mesoblast Resubmits Biologics License Application
09 Jul 2024 //
BIOSPACE
Mesoblast to File BLA for Ryoncil® FDA Approval Next Week
01 Jul 2024 //
GLOBENEWSWIRE
Mesoblast Corporate Presentation At Investor Conference
02 Jun 2024 //
GLOBENEWSWIRE
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
29 Apr 2024 //
GLOBENEWSWIRE
FDA Notifies Mesoblast Available Data from Ph 3 Tria BLA Sub for Remestemcel-L
25 Mar 2024 //
GLOBENEWSWIRE
FDA Grants Mesoblast Orphan-Drug Designation for Revascor
14 Feb 2024 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
30 Jan 2024 //
GLOBENEWSWIRE
Mesoblast plots path to market for twice-rejected cell therapy
22 Sep 2023 //
FIERCE BIOTECH
Mesoblast ReportsFYR and Operational Update for Fiscal Year Ended June 30, 2023
30 Aug 2023 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
29 Aug 2023 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
30 Jul 2023 //
GLOBENEWSWIRE
FDA Accepts Mesoblast`s Resubmission of the BLA for Remestemcel-L
07 Mar 2023 //
GLOBENEWSWIRE
DREAM-HF PIII Results for Mesoblast Cell Therapy in Heart Failure Published
27 Feb 2023 //
GLOBENEWSWIRE
Mesoblast Reports Financial Highlights for Quarter Ended December 31
27 Feb 2023 //
GLOBENEWSWIRE
Mesoblast gives cell therapy a 2nd try with FDA—but no new trial
02 Feb 2023 //
FIERCE BIOTECH
Mesoblast Resubmits BLA to FDA for Remestemcel-L in Children With Sr-aGVHD
31 Jan 2023 //
GLOBENEWSWIRE
